CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 540 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CDK2-IN-39
CAS:CDK2-IN-39 (compound 4) is a CDK2 inhibitor.Fórmula:C14H15N3O4SCor e Forma:SolidPeso molecular:321.352CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Fórmula:C18H14ClNO4SCor e Forma:SolidPeso molecular:375.83CDK2-IN-40
CAS:CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.Fórmula:C16H21N7O2Cor e Forma:SolidPeso molecular:343.384CDK4/6-IN-13
CAS:Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.Fórmula:C25H29N7OCor e Forma:SolidPeso molecular:443.54CDK4/9-IN-1
CAS:CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.Fórmula:C22H34N6O2Cor e Forma:SolidPeso molecular:414.544p38α inhibitor 9
CAS:p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.Fórmula:C27H24FN3O3Cor e Forma:SolidPeso molecular:457.496CDK2-IN-8
CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.Fórmula:C22H25N5O3Cor e Forma:SolidPeso molecular:407.47CDDD11-8
CAS:CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].Fórmula:C24H26N6Cor e Forma:SolidPeso molecular:398.50Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Fórmula:C12H8N4O3Cor e Forma:SolidPeso molecular:256.22CDK9-IN-34
CAS:CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with an IC50 of 0.25 μM. It exhibits cytotoxicity against cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 demonstrates antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.Fórmula:C18H20N4Cor e Forma:SolidPeso molecular:292.38CDK9-IN-13
CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.Fórmula:C27H35N5O2Cor e Forma:SolidPeso molecular:461.6CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Fórmula:C29H36N6O4SCor e Forma:SolidPeso molecular:564.699CDK8-IN-11
CAS:CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.Fórmula:C19H15F3N4O2Pureza:99.74%Cor e Forma:SolidPeso molecular:388.34Ref: TM-T61742
1mg54,00€5mg114,00€10mg178,00€25mg409,00€50mg708,00€100mg982,00€1mL*10mM (DMSO)126,00€CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Fórmula:C29H28FN5OCor e Forma:SolidPeso molecular:481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Fórmula:C27H26ClN5OSCor e Forma:SolidPeso molecular:504.05YL-1-9
CAS:YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].Fórmula:C22H23F3N2O3Cor e Forma:SolidPeso molecular:420.425Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Fórmula:C19H20FN5OSCor e Forma:SolidPeso molecular:385.458CDK9/PARP-IN-1
CAS:CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Fórmula:C38H34F2N8O3Cor e Forma:SolidPeso molecular:688.725YKL-1-116
CAS:YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Fórmula:C34H38N8O3Pureza:98%Cor e Forma:SolidPeso molecular:606.72Anticancer agent 29
Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81Protein Kinase Inhibitor 12
CAS:Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.
Fórmula:C14H14N4OSPureza:98.06%Cor e Forma:SolidPeso molecular:286.35Ref: TM-T204404
1mg185,00€5mg459,00€10mg657,00€25mg1.026,00€50mg1.415,00€100mg1.872,00€200mg2.555,00€CDK9-IN-11
CAS:CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].Fórmula:C20H25N3O4Pureza:98%Cor e Forma:SolidPeso molecular:371.43CDK8-IN-11 hydrochloride
CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.Fórmula:C19H16ClF3N4O2Cor e Forma:SolidPeso molecular:424.8Anticancer agent 30
Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81CDK8-IN-9
CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.Cor e Forma:SolidGSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347LZ9
CAS:LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.Fórmula:C17H11F3N4O2Cor e Forma:SolidPeso molecular:360.29CDK4/6-IN-3
CAS:CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Fórmula:C25H31FN8Pureza:98%Cor e Forma:SolidPeso molecular:462.57Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28P162-0948
CAS:P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.Fórmula:C20H15FN4O2Cor e Forma:SolidPeso molecular:362.357CDK7-IN-18
CAS:CDK7-IN-18 (Compound 15) is a pyrimidine-derived CDK7 inhibitor suitable for studying cancers with transcriptional dysregulation.Fórmula:C22H24F3N7OSPureza:99.28% - 99.54%Cor e Forma:SolidPeso molecular:491.53CDK7-IN-26
CAS:CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Fórmula:C22H22FN6OPSPeso molecular:468.49GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Fórmula:C22H23F4N5OPureza:98.88%Cor e Forma:SolidPeso molecular:449.44LY3143921 hydrate
CAS:LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Fórmula:C16H14FN5O2Pureza:98.43%Cor e Forma:SolidPeso molecular:327.31GSK-3/CDK5/CDK2-IN-1
CAS:GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.433Tanuxiciclib
CAS:Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Fórmula:C15H13FN6OCor e Forma:SolidPeso molecular:312.308Tibremciclib
CAS:Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Fórmula:C28H32F2N8Pureza:98%Cor e Forma:SolidPeso molecular:518.6YK-2168
CAS:YK-2168 is a differentiated selective inhibitor of CDK9.
Fórmula:C16H18ClN5Cor e Forma:SolidPeso molecular:315.80Ref: TM-T200769
Produto descontinuado
